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Abstract
Heart failure (HF) is a major public heart burden among the ageing population. Optimizing 
management of patients remains challenging despite many advances in therapy for this patho-
logy. Natriuretic peptides (NPs) are related to cardiac morbidity and mortality and their use 
in guiding treatment might help. Most data on the value of NPs-guided therapy in chronic HF 
came from centers with high experience in the therapy of HF. Ninety percent of patients had 
preserved left ventricular function. The story is just too complex to have the final answer. The 
numbers of treated patients is insufficient to allow a final decision. Most data derive from 
centers with high skills and were obtained with different assays, different protocols. Many 
questions are open. Can similar results be obtained in less specialized centers? It is undecided 
which NP should be used and how high should be the levels to guide the therapy. Which patients 
might especially benefit from this approach? Is the approach useful in patients with reduced 
systolic function? Is the strategy as useful in the elderly as in younger patients? In spite of these 
limitations, available data suggest that it is reasonable to consider the use of NPs to guide 
the therapy of HF with preserved systolic function. In order to answer some of the questions,  
a multicenter, prospective study began in January 2013. However, NP guided therapy in chronic 
HF will only find acceptance in clinical practice if its use results in therapeutic consequences. 
(Cardiol J 2015; 22, 1: 5–11)
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Introduction
Chronic heart failure (CHF) is a major public 
health burden, especially in elderly patients. While 
modern guidelines on CHF emphasize the impor-
tance of achieving maximally tolerated doses of 
available drugs [1–4], in practice current medical 
treatment is associated with many limitations and 
is often suboptimal. Especially the highest risk-
-patients are often insufficiently treated, a fact 
called ‘risk treatment’ mismatch [5]. Suboptimal 
therapy is due to multiple reasons. In high-risk 
patients, side-effects of drugs are particularly 
frequent. In HF, the clinical assessment is often 
misleading and reliable markers to titrate the the-
rapy are not regularly used. Natriuretic peptides 
(NPs) are valid diagnostic and prognostic markers 
in HF and it has been suggested that measuring 
NPs concentrations should be useful to guide the 
therapy [6–14]. Results derived from this strategy 
have been largely published. We review and discuss 
the present knowledge.
Natriuretic peptides
Recently, Volpe et al. [15] have written a cli-
nical update which is largely based on their expe-
rience which is proven by 13 personal publications. 
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Under physiological conditions in humans NPs are 
produced primarily in the atria where they have 
the highest concentration and are mostly stored 
in granules [16]. However, in response to cardiac 
pathologies with pressure or volume overload, 
ventricular myocytes re-express fetal genes and 
release most of the NPs [17]. Released natriuretic 
propeptide is cleaved into two major molecules, 
a bioactive B-type natriuretic peptide (BNP) and an 
inactive N-terminal pro B-type natriuretic peptide 
(NT-proBNP). Both NPs are used and readily me-
asured with commercially available assays. Some 
aspects of their assessment deserve consideration: 
a) methods differ substantially; b) different anti-
bodies are used in various combinations; c) BNP 
is measured with different calibrators; d) even 
assays using the same antibodies run on different 
instruments and the results vary markedly; e) the 
different half-lives of BNP and NT-proBNP have an 
effect on the measurement of serial concentrations. 
While NT-proBNP assays may have a systematic 
bias at higher concentrations [18], it seems that it 
may be more useful than BNP to ‘guide’ medical 
therapy in HF [19–22].
Strategy NPs-of guided therapy in HF
In 1999, Murdoch et al. [23] described the 
usefulness of plasma BNP concentrations in ti-
trate vasodilator therapy in CHF. Since this early 
publication many papers have reported results of 
‘NPs-guided’ vs. symptoms-guided therapy in CHF. 
As shown in Table 1 many of the cardiologists who 
published results on this argument are members 
of Working Groups on HF and have co-authored 
modern Guidelines on the Diagnosis and Therapy 
of HF [3, 4]. Most published data, i.e. 19 publica-
tions [8, 9, 18, 24–41] are from these cardiologists. 
The number of treated patients in these centers 
outweighs that of patients treated elsewhere and 
the results from the ‘specialized’ and ‘normal’ 
centers are different and sometimes opposed. We 
try to explain some differences.
Changes in plasma levels  
of NPs without therapy
Sequential measurements have shown that 
plasma NPs-levels vary daily and only few fluctu-
ations are due to measurements’ variability [15, 
33, 35, 36]. Also fluctuations in NPs levels are not 
associated with changed symptoms, clinical status 
or edema [10, 11, 14, 15, 25, 33, 35–38].
Most data were obtained with BNP and it 
seems possible that the use of NT-proBNP, with 
its longer half-life would provide better results 
[19–22].
Most fluctuations are related to changing he-
modynamics, such as left ventricular (LV) filling 
pressure, volume, systolic and diastolic function, 
and also right ventricular filling pressure [7, 15, 
41–45] but NPs values cannot be used to estimate 
LV filling pressure [25] and do not differentiate 
between systolic and diastolic dysfunction [18, 25].
Concentrations of NPs fall with increasing 
body mass index [27], increase with age, with decli-
ning renal function, are slightly higher in women 
[7–9, 15, 33–36], and are affected by the occurrence 
of atrial fibrillation [39]. Furthermore, cutoff values 
between normality and pathology differ between 
acute and CHF [15, 43, 44].
The values of NPs as prognostic markers 
may be partially related to their correlation with 
other risk markers, such as LV function, renal 
dysfunction, atrial fibrillation, and age [15, 33, 
35, 39]. Nonetheless, in CHF, a change in BNP 
values of > 20% between monthly follow-ups 
indicates a clinically important change, greater 
than would be expected from spontaneous varia-
tions [7–9, 15, 42, 43]. Indeed, NPs plasma levels 
offer a risk prediction that is independent from 
other factors [38, 43]. As shown in Table 2, per-
sistently elevated or increasing levels of NPs are 
consistently associated with an increased risk of 
cardiac morbidity and hospitalization [37, 43]. 
In stable CHF increased risk is evident from 
a BNP level of 100 pg/mL, with each further 
Table 1. Authors who published the large majority of papers, treated > 8,000 patients, and are mem-
bers of Working Groups on Heart Failure.
References number Frequent authors
[3, 4, 5, 8, 9, 18, 24, 25, 26, 27, 28, 29, 30,  
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 49]
Baggish AL, Cleland JG, Gaggin HK, Januzzi JL Jr, McMurray JJ, 
Troughton RW
[40, 41, 42] Brunner-La Rocca H-P, Buser P, Dubach P, Erne P, Estlinbaum W, 
Maeder M, Pfisterer ME, Rickenbacher P, Suter T, Vuillomenet A
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100 pg/mL increase associated with a 35% in-
crease in risk [7, 39, 43–47]. For NT-proBNP 
the risk is evident from 200 pg/mL and rises 
almost exponentially with increasing levels, es-
pecially above 100 pg/mL [33, 44, 45, 48]. Table 2 
shows the values for NPs which are consistently 
associated with cardiovascular complications in 
patients with CHF.
Changes in plasma levels  
of NPs with therapy
In CHF, NPs levels have been shown to fall in 
response to loop diuretics, angiotensin converting 
enzyme inhibitors, angiotensin receptor blockers 
and mineral receptor antagonists [29–33, 35–49]. 
The response to the beta-blocker metoprolol is 
complex, sometimes with a rise of BNP levels in 
the first 2–3 months followed by a fall [26]. Treat-
ment with the direct renin inhibitor aliskiren was 
also found to reduce NT-proBNP levels [28] but 
this fall was not associated with reduced clinical 
events [50]. Levels of NPs also fall with exercise 
[51], lifestyle interventions [52, 53] and after car-
diac resynchronization therapy [54].
One may assume that in CHF a change in NPs 
levels should be an important independent predic-
tor of clinical outcomes and provide an accurate 
estimate of risk. A failure of NPs concentrations 
to fall in response to the therapy might suggest 
that the risk is not reduced. Therefore, serial mo-
nitoring with NPs levels might deliver powerful 
information about the response to the therapy and 
remaining risk [6–8, 15, 31–35, 40, 43–48].
Different results of different studies  
on NPs-guided therapy
Results of available publications are conflicting. 
Table 3 shows the value of NPs-guided therapy in 
CHF. Positive studies derive almost exclusively 
from those centers which have treated the over-
whelming majority of patients and have published 
the majority of papers on the argument; most of 
these authors are members of Working Groups on 
HF (Table 1). While 6 studies [31, 33, 41, 42, 55, 56] 
reported encouraging trends with the NPs-guided 
therapy in comparison to conventional care, such as 
reduced events in younger patients or in patients 
with reduced LV ejection fraction (in these studies 
a very low NP level was targeted, both in the in-
tervention arm with NP-guided and in arm without 
NP-guided therapy), other studies [45, 57–59] 
presented neutral results. Results derive from dif-
ferent approaches. One of the differences among the 
studies was the patients’ selection. Some centers 
studied outpatients with CHF, while other selected 
patients at discharge from the hospital where they 
had been treated because of an acute cardiac failure. 
Furthermore, target NPs values were chosen em-
pirically. Many studies did not meet their primary 
outcomes in treated patients because the chosen 
basal NPs values were too high to reduce cardiac 
events. For example, the STARBRITE study [59] 
used a goal BNP-value near 450 pg/mL: by the end of 
the trial the BNP-values were quite similar to those 
at hospital discharge and all observed changes were 
within the biological variability of BNP. The chosen 
BNP-value is questionable because the threshold of 
risk for BNP is more than half of this value [7, 15, 
39]. It is thus not surprising that cardiac adverse 
effect rates were high in the BNP-guided arm and 
Table 2. Natriuretic peptides as a risk factor for cardiovascular events in chronic heart failure.
Parameters Value [pg/mL]
B-type natriuretic peptide 100 pg/mL, with each further 100 pg/mL increase associated  
with a 35% increase in risk
N-terminal pro B-type  
natriuretic peptide
200 pg/mL, rises almost exponentially with increasing levels, 
especially above 100 pg/mL
Table 3. Value of natriuretic peptides-guided  
therapy in chronic heart failure.
Useful Authors [Reference]
Yes Bhardwaj et al. [31]
Yes Januzzi Jr [33]
Yes Maeder et al. [41]
Yes Sanders-van Wijk et al. [42]
Yes Berger et al. [55]
Yes Jourdain et al. [56]
No Persson et al. [45]
No Eulings et al. [57]
No Karlstrom et al. [58]
No Shah et al. [59]
8 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 1
similar to the values of the conventional therapy. 
Moreover, the time of collection of basal NPs-values 
was also different among centers. In the PRIMA 
study [57], ‘individualized baseline’ NPs-values 
were collected at the time of hospital discharge 
after an acute cardiac decompensation: a high event 
rate of complications occurred and the NPs-guided 
care was not useful. The time chosen in this study 
to get baseline NPs values is questionable, because 
later experience has shown that NPs-values after 
an acute cardiac decompensation are considerably 
higher than values used in stable CHF and higher 
than the goal that can be achieved with titration of 
therapy [30–36, 40].
In spite of important differences in trial de-
signs, patients’ selection, chosen time, duration 
of collection, type and concentrations of NPs, the 
centers which treated the majority of patients [30, 
32, 55–56] concluded that NPs-guided therapy was 
usually accompanied by numerically and often 
statistically greater up-titration or addition of HF 
therapies. Because of the deficiencies in care that 
are well documented, in present therapy of HF 
[5] by itself this is a desirable effect. Indeed in the 
PROTECT study [38], both arms received more 
intensified therapy than in other studies. Again, it 
must be remembered that most data came from two 
‘specialized’ centers and from authors who have 
published modern Cardiac Guidelines on Diagnosis 
and Therapy of HF (Table 1). The quantity of data 
and number of publications from these centers 
outweigh those from other centers and it is un-
certain if the results from the Working Groups on 
HF can be repeated in less experienced centers.
Not astoundingly, depending on the hete-
rogeneity meta-analyses, the published studies 
give different results. Altogether, available data 
[19–22] suggest that BNP may be less useful than 
NT-proBNP to guide therapy in HF. Indeed, in 
a meta-analysis [29] NT-proBNP-guided therapy 
reduced death by 28% (p = 0.007) and HF-rela-
ted hospitalization by 47% (p = 0.003), whereas 
BNP-guided therapy reduced these outcomes by 
19% (p = 0.37). However, BNP was used in few 
centers and the majority used NT-proBNP. Thus 
the comparative merits of the two p values cannot 
be fully accepted.
NPs are useful in the care of acute HF also in 
the presence of concomitant diseases [25] but this 
knowledge should not be extrapolated for their 
use in CHF [39]. Little is known about the validity 
of using NPs-guided care in patients with CHF 
associated with atrial fibrillation, renal dysfunction 
and other diseases.
Elderly patients seem to have very high values 
of NPs and in a meta-analysis [22] most studies 
have suggested that the benefits of NPs-guided 
therapy are primarily limited to younger patients. 
This effect is especially evident in two studies [29, 
40]. On the contrary, another study [36] came to 
the opposite conclusion and showed that the NPs-
-guided therapy was more effective in the elderly 
than in the younger patients. The results are sum-
marized in Table 4. Thus, it is yet unclear if age 
may affect the use of NPs-guided care. Since CHF 
is the most frequent cause of morbidity and mor-
tality for patients > 65 years of age and is a major 
public heart burden among the ageing population, 
confirming these findings would reduce the utility 
of NPs-guided care in elderly patients with CHF.
Lastly, HF with preserved systolic function 
differs from HF with reduced systolic function. 
However, 90% of patients treated with NPs-guided 
care had a normal ejection function [39]. Present 
data seem to indicate that NPs-guides care might 
be less efficacious in patients with reduced ejection 
function and high NT-proBNP levels [42, 48]. If 
confirmed, these findings would reduce the utility 
of NPs-guided care in this type of CHF.
Safety of NPs-guided therapy
None of the published studies noted an impor-
tant increase in untoward reactions which might be 
related to NPs-guided care. However, the number 
of treated patients was too small to exclude some 
side-effects and the two ‘specialized’ centers using 
this approach do not represent the use in normal 
conditions. Therefore, we don’t know if the use of 
NPs-guided cardiac care in less specialized centers 
will be safe.
NPs-guided therapy and quality of life
In a study [48] on NPs-guided therapy, no 
difference was detected in comparison with con-
ventional care in improving the quality of life, but 
in another study [50] NPs-guided therapy was 
Table 4. Value of natriuretic peptides-guided the-
rapy in elderly patients with chronic heart failure.
Useful Authors [Reference]
No Savarese et al. [22]
No Lainchbury et al. [29]
No Pfisterer et al. [40]
Yes Motiwala and Januzzi [35]
www.cardiologyjournal.org 9
Giuseppe Cocco, Paul Jerie, Assessing the benefits of natriuretic peptides-guided therapy in CHF
superior to conventional care in improving the 
quality of life. Thus at present we do not know 
if NPs-guided therapy is useful in improving the 
quality of life.
NPs-guided therapy and cardiac function
Important data show that high NPs levels 
on the long term might indicate a deleterious LV 
remodeling [8, 15]. A study [37] has shown that 
NPs-guided care reduces NPs levels and speculates 
whether the negative ventricular remodeling might 
be reduced by NPs-guided care. This is a wishful 
speculation.
Costs of NPs-guided therapy
Some studies [41, 60, 61] show that in am-
bulatory settings, NPs-guided care would reduce 
the need of repeated hospitalizations and should 
be cost-effective. However, studies with different 
patients, trial designs and in different heath care 
systems are missing and at present it cannot be 
concluded that NPs-guided care is cheaper than 
conventional care [39].
Non-response to NPs-guided therapy
Some patients do not benefit from NPs-guided 
care. In some of these patients, selected NPs values 
were very high and in spite of serial measurements 
and changes in the medical therapy the cardiova-
scular complications were insufficiently reduced. 
It might be thought that ‘some’ reduction of NPs 
levels might still be useful. Indeed, in two studies 
with overall neutral results [56, 57] those patients 
in whom NT-proBNP decreased to a significant 
extent had a better clinical outcome.
Conclusions, questions, and future
Optimizing management of patients with 
CHF remains challenging despite many signi-
ficant advances in drug and device therapy for 
this pathology. Although a large body of evidence 
from clinical trials supports multiple therapies, in 
‘real-world’, utilization of these well-established 
treatments remains inconsistent and outcomes are 
suboptimal in patients with CHF. NPs-guided care 
has been used with the aim to improve insufficient 
therapy. The story is just too complex to have the 
final answer. At present, we have data from about 
8,000 patients who were treated with this system, 
and 90% of them preserved systolic function [39]. 
The number is insufficient to allow a final decision, 
especially if one considers that most of the data 
derived from two centers with high skills in the 
therapy of HF and that data were obtained with 
different NPs assays, from different patients, with 
different sampling protocols, with different follow-
-up lengths and many more. Several problems 
exist and must be taken into account. In HF, NPs 
are produced in the heart and, to a lesser extent, 
in other organs [15]. The diagnosis of HF encom-
passes many pathologies and types of disease, and 
many factors influence the production and amount 
of NPs. It has been demonstrated that the values 
of NPs change according to the time of assessment 
and changing severity of HF [15]. Present data have 
been collected by using either BNP or NT-proBNP. 
However, new biomarkers have been introduced, 
such as galectin-3 and soluble ST2. It has been 
suggested [39] that these new markers could be 
useful for the selection of patients who would be 
likely to benefit from special therapies. In the fu-
ture we may perhaps use special biomarkers, learn 
more about the pathophysiology of some cardiac 
diseases, and thus use a more appropriate therapy.
Still, many questions are open about the NPs-
-guided therapy for CHF and they are illustrated 
in Table 5. Because of the unanswered questions, 
present Cardiology Guidelines from Europe and 
Australia have not yet given any recommendation 
on the use of NPs-values to guide therapy in CHF. 
Many authors who have published the majority of 
publications on this strategy have also contributed 
to the Cardiology Guidelines from the American 
Table 5. Open questions about the natriuretic 
peptides (NPs)-guided therapy in chronic heart 
failure (HF).
Should B-type natriuretic peptide or N-terminal  
pro B-type natriuretic peptide be used?
How high should be the target NPs value at  
selection and during guided therapy?
Is NPs-guided care as useful in the elderly as in  
younger patients?
NPs-guided care was mainly used in experienced 
centers. Can the strategy be useful in less  
specialized centers?
Might patients discharged from the hospital after 
a worsening of HF and who are at high risk benefit 
from NPs-guided care?
Might high risk patients, such as those with atrial  
fibrillation and renal dysfunction, benefit from  
NPs-guided care?
NPs-guided care was used mostly in patients with 
diastolic HF. Might the approach also be useful in  
patients with reduced systolic function?
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College of Cardiology and American Heart As-
sociation, and these guidelines give a class IIa 
recommendation (reasonable to consider) to the 
NPs-guided care in CHF and also state that the 
utility is not established to reduce hospitalization 
and mortality, a class IIb recommendation [3]. 
Because of the present uncertainties, the United 
States National Heart Lung Blood Institute has 
funded the GUIDing Evidence using Biomarker 
Intensified Treatment (GUIDE-IT, NCT01685840), 
a prospective, multicenter, randomized trial that 
will follow 1,100 patients with HF and LV ejection 
fraction < 40%. Patients will be enrolled at the 
time of discharge from the hospital and will be 
randomized to either usual care or to NT-proBNP-
-guided care, with a target value < 1,000 pg/mL. 
Forty centers from Canada and United States have 
been participating and the study began in January 
2013. Primary endpoints are time to cardiovascular 
death or recurring hospitalization because of HF. 
Secondary endpoints are: a) all-cause mortality, 
b) cumulative morbidity, c) health-related quality of 
life, and d) costs and cost-effectiveness, and safety.
To conclude, according to the message from 
experienced authors [39], present data suggest that 
the use of NPs may be safe and effective. Nonethe-
less, in spite of many published data, the utility of 
NPs-guided care in CHF is still unknown. We need 
answers to the important open questions. NPs-
-guided therapy of CHF will only find acceptance 
in clinical practice if its use results in therapeutic 
consequences, in improvements of prognosis by 
pharmacologic management.
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